Diabetic Emergencies DKA, HHS, Hypoglycemia. Disclosure. Learning Objectives

Similar documents
Diabetic Ketoacidosis

Management of Hyperglycemic Crises

DKA : Diabetic Ketoacidosis & HHS: Hyperlgycemic Hyperosmolar Syndrome Protocol. Glycemic Task Force September 2014

ADVOCATE CHRIST MEDICAL CENTER DKA (DIABETIC KETOACIDOSIS) TREATMENT GUIDELINES

AACN PCCN Review. Endocrine

Diabetic Emergencies: Ketoacidosis and the Hyperglycemic Hyperosmolar State. Adam Bursua, Pharm.D., BCPS

Diabetic Ketoacidosis

Type 2 Diabetes Mellitus Insulin Therapy 2012

Diabetic Ketoacidosis (DKA) Critical Care Guideline Two Bag System

Vinaya Simha, M.D. Assistant Professor, Division of Endocrinology

Hyperosmolar Hyperglycemic State (HHS) Erica Kretchman DO October

SARASOTA MEMORIAL HOSPITAL NURSING PROCEDURE

Multiple c hoice q uestions

DKA/HHS Pathway Phase 1 (Adult) Insulin Potassium Bicarbonate

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Learning Objectives. Perioperative SWEET Success

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Insulin Prior Authorization Criteria For Individuals who Purchased BlueCare / KS Solutions products

DRUG ALLERGIES WT: KG

Insulin Prior Authorization Criteria For Individuals Who Purchased BlueCare/KS Solutions/EPO Products

Nothing to disclose. Disclosure

New Therapies for Diabetes Management: Hope or Headache?

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

Insulin Prior Authorization with optional Quantity Limit Program Summary

Mixed Insulins Pick Me

APPENDIX American Diabetes Association. Published online at

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Type 1 Diabetes-Pathophysiology, Diagnosis, and Long-Term Complications. Alejandro J de la Torre Pediatric Endocrinology 10/17/2014

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

With Dr. Sarah Reid and Dr. Sarah Curtis

Inpatient Glycemic Management:

INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

In-hospital management of diabetes

Nph insulin conversion to lantus

CDE Exam Preparation Presented by Wendy Graham RD CDE May 4, 2017

Anne Leake, PhD, APRN, BC-ADM ECHO Diabetes Learning Group 4/4/18. High Sugar / Hyperglycemia: Causes, Complications and Management

Diabetic ketoacidosis and. adults. By Dr Karimifar Assistant Prof. of Endocrinology Isfahan University of Medical Sciences

Insulin Regimens: Hitting Glycemia Targets

The Realities of Technology in Type 1 Diabetes

1. Continuous Glucose Monitoring

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

Rebecca Newberry APRN MS CDE

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Adjusting Insulin Doses

INSULIN 101: When, How and What

Case Study: Competitive exercise

DIABETIC KETOACIDOSIS (DKA) K E M I A D E Y E R I, P G Y - 1

The Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It

Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Diabetes in Pregnancy

Implementing Hospital Policies & Protocols

Making the Most of Continuous Glucose Monitoring

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

The principles of insulin adjustment guidance

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Subject Index. Breastfeeding, self-monitoring of blood glucose 56

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter

Inpatient Diabetes and Hyperglycaemia. Philip Dyer Heart of England NHS Foundation Trust Birmingham

Date of birth: Type 2 Other: Parent/guardian 1: Address: Telephone: Home: Work: Cell: address: Camper physician / health care provider:

I have no financial disclosures

Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

I. General Considerations

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

DIABETES AND PREGNANCY. CDE Exam Preparation March 22 & 27, 2018 Presented by Wendy Graham RD CDE Mentor

COMPLIANCE WITH THIS DOCUMENT IS MANDATORY

Diabetes Head to Toe May 31, 2017

Virginia Diabetes Medical Management Plan (DMMP)

Published in

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

ADMIT DIABETIC KETOACIDOSIS (DKA) PLAN - Phase: Begin Immediately/Emergency Center

Diabetes Medical Management Plan

Improving Glycemic Control in the Critical Care

Next steps for success.

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Glycemic Control IU Health Diabetes Centers

Recent Advances in the Management of Diabetes

DKA Adult ICU Powerplan

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Name: DOB: Date: School Year: _ _

8/13/2016. Insulin Basics. Rapid-Acting Insulin Analogs. Current Insulin Products and Pens. Basal Insulin Analogs. History of Insulin Therapy

Injecting Insulin into Out Patient Practice

For The Management Of. Diabetic Ketoacidosis

Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

DEMYSTIFYING INSULIN THERAPY

Pharmacy Plan Guidance

Transcription:

Diabetic Emergencies DKA, HHS, Hypoglycemia October 2018 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Disclosure Michael McDermott has no conflict of interest or relationships to disclose in relation to this educational activity. Learning Objectives Explain the pathophysiology of diabetic ketoacidosis (DKA) and Hyperosmolar Hyperglycemic Syndrome (HHS). Review the diagnostic approach to DKA and HHS and the distinction between the two conditions. Discuss the treatment of DKA and HHS. Review the treatment of inpatient hypoglycemia. Emphasize strategies to prevent inpatient hypoglycemia.

Diabetic Ketoacidosis Clinical Setting Type 1 DM (70-90%) New Onset Poor Compliance Precipitating Event Type 2 DM (10-30%) Precipitating Event Precipitating Events Infection Adrenal Crisis Acute Abdomen Ischemic Extremity Pulmonary Embolus Myocardial Infarction Cerebrovascular Event New Onset Type 1 Diabetes Pathogenesis Insulin Deficiency Absolute h Counterregulatory Hormones Insulin Deficiency Relative h Lipolysis h Ketogenesis h Proteolysis h Gluconeogenesis i Glucose Utilization h Glycogenolysis Minimal Ketogenesis i Alkali Reserve Hyperglycemia Ketoacidosis Dehydration Hyperosmolarity DKA HHS Kitabchi A, Diabetes Care 2009;32:1335-43

Water and Electrolyte Deficits Plasma Osmolality and Mental Status Plasma Osmolality Mental Status Kitabchi A, JCEM 2008;93:1541-52 Useful Calculations Anion Gap Na + -(Cl - + HCO3 - ) Normal Range: 7-13 mmol/l Serum Osmolality 2 x (Na + ) + (Glucose/18) + (BUN/2.8) Normal Range: 285-295 mosm/kg

Diabetic Ketoacidosis Diagnosis Glucose > 250 mg/dl HCO3 < 18 meq/l ph < 7.30* Anion Gap > 15 Ketones Positive (Urine, Serum) *Arterial ph best but venous ph OK Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Severity DKA MILD MODERATE SEVERE Glucose: > 250 mg/dl ph: 7.25-7.30 HCO 3: 15-18 meq/l Ketones: positive Sensorium: alert Glucose: > 250 mg/dl ph: 7.0-7.24 HCO 3: 10-14 meq/l Ketones: positive Sensorium: alert/drowsy Glucose: > 250 mg/dl ph: < 7.0 HCO 3: < 10 meq/l Ketones: positive Sensorium: stupor/coma HHS Glucose: > 600 mg/dl ph: > 7.30 HCO 3: > 18 meq/l Ketones: small Sensorium: stupor/coma Kitabchi A, Diabetes Care. 2009;32:1335-43 IV Fluids Rehydrate: Monitor + Correct Hyponatremia Insulin Correct Hyperglycemia Potassium Prevent Hypokalemia Bicarbonate? Correct Severe Acidosis (ph < 6.9) Treat Precipitating Cause

IV Fluids 1 st Hour: NS, 15 20 ml/kg/h (1.0 1.5 Liters) Maintenance: ½ NS, 250 500 ml/h if serum Na h or Normal NS, 250-500 ml/h if serum Na Low Change to D5 when BG < 200 mg/dl (DKA) or < 300 mg/dl (HHS) Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51 Insulin (Regular) IV Bolus 0.1 U/kg, then Infusion 0.1 U/kg/hr If BG not i by 10% in 1 hour, IV bolus 0.14 U/kg and continue infusion at the previous rate Decrease rate to 0.02-0.05 U/kg/hr when BG < 200 mg/dl (DKA) or < 300 mg/dl (HHS) Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51 Insulin Given by Different Routes Mild-Moderate DKA RCT: IV vs SQ vs IM Insulin Glucose Ketones Conclusion: In Mild-Moderate DKA, Insulin May Be Given IV, SQ or IM Kitabchi A, JCEM 2008;93:1541-52

Diabetic Ketoacidosis SQ insulin analogs may be used in mild moderate DKA in ED or inpatient Butkiewicz E, Diabetes Care 1995;18:1187 90 Fisher J, N Engl J Med 1977;297:238 47 Nyenwe E, Kitabchi A, Diab Res Clin Pract 2011; 94:340-51 Diabetic Ketoacidosis IV Insulin + SQ Glargine RCT: IV Insulin vs IV Insulin + Glargine 0.25 U/Kg within 10 hours of IV Start Open Bars (N=13) No Glargine Closed Bars (N=12) Glargine Average Glucose Percent Rebound h Glucose Conclusion: In DKA, SQ Glargine Given with IV Insulin Reduces the Risk of Future Rebound Hyperglycemia without Increasing Hypoglycemia University of Colorado DKA Study Hsia E, J Clin Endocrinol Metab 2012;97:3132-7 Potassium (check every 2 hours) Serum K + > 5.2 meq/l: Don t give K + Serum K + 3.3-5.1 meq/l: Give K + 20-30 meq/l Serum K + < 3.3 meq/l initially: Delay Insulin Rx. Give K + 20-30 meq/h until serum K + > 3.3 meq/l Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51

Bicarbonate ph < 6.9: Na Bicarbonate, 2 amps (100 mmol) in 400 ml H20 with 20 meq KCL, at rate of 200 ml/h for 2 hr until the venous ph is > 7.0 ph > 6.9: Na Bicarbonate therapy not required Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51 Phosphate Not indicated in most DKA patients Potential hypophosphatemic complications: Add 20 30 meq/l K Phosphate to IV fluids Monitor serum calcium level Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51 Hypercoagulable State DKA: prophylactic heparin use may be beneficial HHS: full anticoagulation if no contraindications Kitabchi A, Diabetes Care 2009;32:1335 43 Wilson JF, Ann Intern Med 2010; ITCI-3, Jan 1 Nyenwe E, Diab Res Clin Pract 2011; 94:340-51

Glucose < 200 mg/dl HCO3 > 18 meq/l ph > 7.30 Diabetic Ketoacidosis Resolution Anion Gap < 13 Ketones Improving (Urine, Serum) May not become negative for days Diabetic Ketoacidosis Ketone Response to Nitroprusside Measures Acetoacetate B Hydroxybutyrate Predominates Early; Converts to Acetoacetate With Caveat Ketones Measured by NP May Worsen Transiently Before Improving Protocol Use One Kitabchi A, Diabetes Care 2009;32:1335-43

UCH Protocol Use One Flow Sheet Use One Pitfalls of Precipitating Cause: don t fail to treat Cerebral Edema: don t correct BG too rapidly Relapse: don t turn off the IV insulin too soon Relapse: remember to give SQ long acting insulin before you stop the IV insulin

Mortality Mortality DKA: ~ 4% HHS: ~ 15% Adverse Prognostic Factors Coma Hypotension Age Extremes Hypoglycemia Definitions Hypoglycemia Glucose < 70 mg/dl Severe Hypoglycemia Glucose < 55 mg/dl, or Severe Symptoms, or Required IV Glucose or IM Glucagon Most Common Acute Complications Coma Seizures Dysrhythmias Myocardial Infarctions Death Hypoglycemia Complications

Hypoglycemia Raise Glucose to > 70 mg/dl ASAP Oral Glucose: 30 gm Recheck BG 20 minutes later Repeat oral glucose if BG still < 70 mg/dl Intravenous Glucose (D50): 25-50 gm Intramuscular Glucagon: XXXX Recognize Which Medications Cause Hypoglycemia Insulin Sulfonylureas Meglitinides Avoiding Hypoglycemia All Patients Insulin Preparations 2018 Generic Name Peak Duration Inhaled Ins. Afrezza 1-2 hr 2-4 hr Aspart Fiasp 1-2 hr 2-4 hr Aspart Novolog 1-2 hr 3-5 hr Glulisine Apidra 1-2 hr 3-5 hr Lispro Humalog 1-2 hr 3-5 hr Detemir Levemir Minimal 20-24 hr Glargine Lantus/Basaglar Minimal 22-24 hr Glarg U300 Toujeo None 24-26 hr Degludec Tresiba None 36 hr NPH Humulin-N 8-12 hr 12-20 hr Regular Humulin-R 2-4 hr 6-8 hr U500 Humulin-R U500 8-12 hr 12-16 hr

Basal Insulin Monitor HS to AM BG Trend ( i < 30 mg/dl overnight) Short-Acting Insulin Avoiding Hypoglycemia Insulin Therapy Mealtime Doses: Take Before the Meals Carbohydrate Counting: Learn to Do Accurately Correction Doses: Don t Stack (4 Hour Duration) Avoiding Hypoglycemia Sick Day / NPO Day Rules: Educate Sick Days / Low Intake Days / NPO Days Basal Insulin: i 33-50% (don t stop) Mealtime Insulin NPO: Stop Low Intake: i 50% Correction Insulin: Every 6 Hours for h BG Sulfonylureas/Meglitinides: Stop Avoiding Hypoglycemia Insulin Therapy Adjust Insulin For CKD or AKI egfr 10-50 ml/min: i total insulin dose 25% egfr < 10-50 ml/min: i total insulin dose 50%

Avoiding Hypoglycemia Insulin Therapy Continuous Glucose Monitoring Professional CGM Every 6 Months, or Personal CGM Continuously Glucose Sensors 2018 Professional Devices Abbott Flash Libre Pro Dexcom G4 Platinum Medtronic ipro 2 BG Data Blinded to the Patient while Wearing Keep Records Downloaded during Visit to MD/DO/CNS/NP/PA/CDE Carlson A. Diabetes Technol Therap 2017; 19(S2), S4-S12 Glucose Sensors 2018 Personal Devices Dexcom G6 Guardian-3 Freestyle Libre Flash BG Data Real-Time to Patient Every 5 Minutes Trend arrows to indicate direction and rate of change Alarms for current or impending Hypo or Hyper Levels Download to provider at next visit

Glucose Sensors 2018 Professional Devices Detect Patterns not Seen with SMBG Glucose Sensors Interpretation and Recommendations Interpretation: hypoglycemia occurring most often mid-morning and mid-afternoon. Recommendations: improve fasting glucose so that correction insulin doses are not needed. Use a less aggressive C:I ratio for breakfast and lunch and less aggressive CF during the day. Glucose Sensors Interpretation and Recommendations Interpretation: hypoglycemia occurs most often overnight. Recommendations: improve dinner coverage; change to less aggressive CF after dinner and at bedtime to avoid nighttime hypoglycemia since patients are less aware of hypoglycemic episodes while sleeping.

Insulin Pumps - 2018 Medtronic 670G Guardian Sensor 3 Hybrid Closed Loop Tandem T-Slim X2 +/- DexCom G5 [HCL in Development] OmniPod +/- DexCom G5 [HCL in Development] V-Go Patch Pump Asante Snap Sooil DiabecareIIS Hybrid Closed Loop Insulin Delivery Predictive Glucose Management Medtronic 670G Hybrid Closed Loop Insulin Delivery During Pregnancy Stewart ZA. N Engl J Med 2016; 375:644-54

Diabetic Emergencies Summary Find Precipitating Cause of the Event Treat DKA, HHS with Insulin, Fluids, KCl Monitor Closely and Use a Flow Sheet Transition to SQ Insulin before DC IV Insulin Hypoglycemia: Treat with Glucose (PO, IV) or Glucagon (IM) Prevention of Hypoglycemia: Top Priority Thank You